Please join us Monday, June 1st 7-9pm ET for this FREE virtual webinar on Facts vs. Myths in #EGFR + #lungcancer. All are welcome - register today at virtualcec.com! Questions will be answered from the audience live by the experts! EGFR Resisters #lcsm CEC Oncology #ASCO20

We are excited to share our 1st webinar of a 3-part series on Progression & Resistance in #EGFR+ #lungcancer sponsored by Blueprint Medicines. Please join @sloan_kettering Drs. Helena Yu & Joseph Minhow Chan, MD, PhD to learn more about #smallcelltransformation. #lcsm player.vimeo.com/video/501299277

Congratulations to Noura Choudhury, MD on her Conquer Cancer, the ASCO Foundation ASCO Young Investigator Award. I'm lucky to co-mentor her with Helena Yu . She has an interesting trial combining amivantamab and lazertinib in patients with EGFR mutant NSCLC progressing in the CNS (almost open!).

#ASCO21 Great perspective on ctDNA in NSCLC trials by Lecia Sequist, MD, MPH ctDNA already matches target to Tx New trials may use ctDNA to: - escalate/de-escalate Tx (Helena Yu's trial below) - identify duration of Tx - prevent/Tx acqd resistance - select adjuvant tx OncoAlert

Just published #OnlineFirst: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell #LungCancer by Pasi Janne and colleagues. bit.ly/39rIizu. Dana-Farber Daiichi Sankyo US

Available Cancer Discovery: Phase I study of Patritumab Deruxtecan (HER3-DXd, a HER3 directed antibody drug conjugate) in #EGFR mutant NSCLC post-TKI. Encouraging RR 39%, mPFS 8.2m across various mechanisms of TKI resistance and HER3 expression levels. #LCSM cancerdiscovery.aacrjournals.org/content/early/…

Excited to share our latest work from Charlie Rudin lab about lung adeno-to-squamous cell carcinoma transdifferentiation. Another huge team effort to identify drivers and therapeutic targets for this fascinating and clinically relevant phenomenon. rdcu.be/czDn6

Learn about EA5182, our #clinicaltrial for patients with metastatic, EGFR-mutant #NSCLC, led by Helena Yu of @sloan_kettering. More: blog-ecog-acrin.org/trial-spotligh… cc: @DrSteveMartin #lungcancer #lcsm

There's still time to register for tomorrow's webinar, The Evolving State of the Science in #EGFRm #NSCLC. Log in at 6:30pm EDT for 1.0 free CME/CE credit! Still need to register? ➡️ hubs.ly/Q01fD_hq0 #MedEd #IPCE #LCSM Helena Yu Jill Feldman

The 4th Annual #EGFRSummit22 Call for Abstracts is officially OPEN! If you're a Jr Faculty, Fellow, or Post doc conducting active research in #EGFR, submit your work for a chance to share your data in Chicago this November! Submit here: ceconcepts.com/egfrsummit-22 EGFR Resisters

APOBEC, a prominent mutational signature in oncogenesis, initiates from the activity of the A3A & A3B cytosine deaminases. In this original article, investigators studied its association with RTK-driven lung cancer 🫁 including resistance to treatments💊 annalsofoncology.org/article/S0923-…

The CFS meeting in NY on November 9-11 is a great opportunity to hear all of the latest advances. Join me and my thoracic oncology colleagues for the lung cancer session Friday morning! Use code CFS22SL35 for 35% of registration. #LCSM Register today at bit.ly/3OdCITO

Dr. Monica Chen presents an exciting actively enrolling study of amivantamab-lazertinib in pts w/ EGFRm NSCLC with progressive CNS disease EGFR Resisters Research Summit. We need more studies in this space! #EGFRSummit22. Helena Yu

Dr. Joseph Minhow Chan, MD, PhD starting off the alumni presentations strong 💪 with his work on understanding lineage plasticity in #lungcancer under RB1/TP53 loss. 🫁 #EGFRSsummit22 EGFR Resisters #lcsm #lcam

Using tissue-based #genomic analysis, this study shows that patients with #EGFR-mutant lung cancer have an improved survival when treated with first-line #osimertinib based on progression. bit.ly/3Fxt6Su Helena Yu Noura Choudhury, MD Antonio Marra #LCSM

Patients w/EGFR-mutant #lungcancer treated w/first-line #osimertinib have improved survival w/treatment adaptation based on mechanisms of resistance identified at time of progression using tissue based genomic analysis. bit.ly/3LOsbzW Helena Yu #LCSM

Are you living with #EGFR+ #lungcancer and wondering what's next once #osimertinib stops working? EGFR Resisters co-founders, Jill Feldman & Ivy Elkins, along with Christine Lovly, MD, PhD, FASCO & Helena Yu will be sharing updates during a Facebook Live on 5/11 fb.me/e/T6HK8iql

Recap of Memorial Sloan Kettering Cancer Center #lungcancer highlights from #ASCO24: Bob Li presented results showing sotorasib as potential as a first-line treatment for certain lung cancers, and Helena Yu presented a new drug combo for EGFR-mutated lung cancers. #lcsm mskcc.org/news/msk-resea…